THE TRANSITION TOWARS PERSONALIZED MEDICINE
2011
2014
TIME LINE
Bockemeyer. J Clin Oncol.
2009
Data 2008 Data 2014
KRAS-MUT
Any RAS-MUT
KRAS Ex 2
N = 136
RAS EX 2-4
N = 167
Δ
22%
Bockemeyer. ASCO. 2014
OBJETIVE RESPONSE (QT-Cmab)
KRAS-WT E.2: 57%
Any RAS-WT: 61%
KRAS-MUT E2: 34% Any RAS-MUT: 36%
30
